Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB by Ingrid Teige, Linda Mårtensson, Björn L. Frendéus

Get full text

594 BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment by Laetitia Fend, Eric Quemeneur, Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendeus

725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy by Monika Semmrich, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Mathilda Kovacek, Petra Holmkvist, Carolin Svensson, Therese Blidberg, Carl Roos, Andres McAllister, Mimoza Demiri, Marie Borggren, Ingrid Karlsson

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors by Laetitia Fend, Eric Quemeneur, Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Carolin Svensson, Christelle Remy, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén

Get full text

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma by Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang

Get full text

1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy by Monika Semmrich, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Mathilda Kovacek, Petra Holmkvist, Carolin Svensson, Therese Blidberg, Andres McAllister, Marie Borggren, Ingrid Karlsson, Mark Cragg, Mimoza Bodén, Kirstie Cleary, Osman Dadas, Benjamin Duell, Jan Anders Nilsson, Stephen Beers, Sean Lim, Johan E Wallin

Domain binding and isotype dictate the activity of anti-human OX40 antibodies by C Ian Mockridge, Kerry L Cox, Martin J Glennie, Mark S Cragg, Monika Semmrich, Linda Mårtensson, Ingrid Teige, Jordana Griffiths, Khiyam Hussain, Hannah L Smith, Theodore Sanders, Jinny Kim, Tatyana Inzhelevskaya, Chris A Penfold, Alison L Tutt, HT Claude Chan, Vikki English, Ruth F French, Aymen Al-Shamkhani, Bjorn L Frendeus, Jane E Willoughby

Get full text

757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab by Michael Chisamore, Jeffrey Yachnin, Ana Carneiro, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Andres McAllister, Marie Borggren, Ingrid Karlsson, Mark Cragg, Lars Ny, Zsuzsanna Pápai, Kristoffer Staahl Rohrberg, Kirstie Cleary, Jan Anders Nilsson, Sean Lim, Johan E Wallin, Istvan Lang, Harriet Walter, Rikke H Lovendahl Eefsen, Edvard Abel, Robert Oldham, Susanne Gertsson